Companies › ImmVira Pharma
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| T3011 Oncolytic adenovirus | – | Phase 2 | Nonmuscle-invasive Bladder Cancer | Dec 2028 |
| MVR-T3011 Unclear mechanism for code-named investigational drug | – | Phase 1 | Solid Tumor | Jan 2027 |
| C5252 Oncolytic herpes virus | – | Phase 1 | Glioma, Malignant | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04370587 | MVR-T3011 | Phase 1 | Solid Tumor | Oncology | Jan 2027 |
| NCT07243340 | C5252 | Phase 1 | Glioma, Malignant | Oncology | Dec 2027 |
| NCT06971614 | T3011 | Phase 2 | Nonmuscle-invasive Bladder Cancer | Oncology | Dec 2028 |
No annotated target.
–
Allotera Therapeutics PersonGen BioTherapeutics (Suzhou) Vyriad Shanghai Juncell Therapeutics Scancell
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.